Amdocs Limited (DOX) Shares Sold by Robecosam AG
Robecosam AG decreased its holdings in Amdocs Limited (NASDAQ:DOX) by 39.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,550 shares of the technology company’s stock after selling 1,000 shares during the quarter. Robecosam AG’s holdings in Amdocs were worth $102,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds have also made changes to their positions in DOX. Delpha Capital Management LLC bought a new position in Amdocs in the fourth quarter worth $109,000. Focused Wealth Management Inc bought a new position in Amdocs in the fourth quarter worth $157,000. American International Group Inc. bought a new position in Amdocs in the fourth quarter worth $199,000. CENTRAL TRUST Co raised its holdings in Amdocs by 45.0% in the fourth quarter. CENTRAL TRUST Co now owns 3,388 shares of the technology company’s stock worth $222,000 after purchasing an additional 1,052 shares in the last quarter. Finally, Cerebellum GP LLC bought a new position in Amdocs in the fourth quarter worth $246,000. 93.46% of the stock is owned by institutional investors.
Amdocs Limited (NASDAQ:DOX) opened at $68.59 on Wednesday. Amdocs Limited has a twelve month low of $60.30 and a twelve month high of $71.37. The firm has a market capitalization of $9,887.58, a price-to-earnings ratio of 18.68, a PEG ratio of 2.35 and a beta of 0.55.
The business also recently declared a quarterly dividend, which will be paid on Friday, April 20th. Stockholders of record on Friday, March 30th will be issued a dividend of $0.25 per share. The ex-dividend date of this dividend is Wednesday, March 28th. This is an increase from Amdocs’s previous quarterly dividend of $0.22. This represents a $1.00 annualized dividend and a dividend yield of 1.46%. Amdocs’s dividend payout ratio (DPR) is presently 28.39%.
A number of equities analysts have issued reports on the company. ValuEngine upgraded Amdocs from a “hold” rating to a “buy” rating in a report on Thursday, March 1st. Stifel Nicolaus increased their price objective on Amdocs from $72.00 to $75.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. Oppenheimer reiterated a “buy” rating and issued a $77.00 price objective on shares of Amdocs in a report on Wednesday, January 31st. BidaskClub downgraded Amdocs from a “sell” rating to a “strong sell” rating in a report on Tuesday, December 5th. Finally, Zacks Investment Research upgraded Amdocs from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $70.71.
WARNING: “Amdocs Limited (DOX) Shares Sold by Robecosam AG” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.thecerbatgem.com/2018/03/14/amdocs-limited-dox-shares-sold-by-robecosam-ag.html.
Amdocs Limited is a provider of software and services for communications, entertainment and media industry service providers. The Company develops, implements and manages software and services associated with business support systems (BSS), operational support systems (OSS) and network operations to enable service providers to introduce new products and services, process orders, monetize data, support new business models and enhance their understanding of their customers.
Want to see what other hedge funds are holding DOX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amdocs Limited (NASDAQ:DOX).
Receive News & Ratings for Amdocs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amdocs and related companies with MarketBeat.com's FREE daily email newsletter.